Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Forxiga | Dapagliflozin | Diabetes mellitus, type 2 | Do not list | Complete | ||
Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | ||
Forxiga | dapagliflozin | Chronic kidney disease | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete | ||
Fosavance 70/5600 | Alendronate sodium / cholecalciferol | Osteoporosis | List in a similar manner to other drugs in class | Complete | ||
Fosrenol | Lanthanum carbonate hydrate | Hyperphosphatemia, end-stage renal disease | Do not list | Complete | ||
Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | ||
Fycompa | Perampanel | Epilepsy, partial onset seizures | List with criteria/condition | Complete | ||
Fycompa | Perampanel | Epilepsy, primary generalized tonic-clonic seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Galafold | migalastat | Fabry Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Galexos | Simeprevir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Gazyva | Obinutuzumab | Follicular Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Gazyva | Obinutuzumab | Follicular Lymphoma (previously untreated) | Do not reimburse | Complete | ||
Gazyva | Obinutuzumab | Chronic Lymphocytic Leukemia | Reimburse | Complete | ||
Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | ||
Gilenya | Fingolimod | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Giotrif | Afatinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse | Complete | ||
Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete |